Clinical characteristics of patients with VTE (n =61)
| Clinical characteristic . | Value . |
|---|---|
| Median age at study entry, y (IQR) | 60 (50-66) |
| Sex, n (%) | |
| Female | 21 (34.4) |
| Male | 40 (65.6) |
| Site of thrombotic event, n (%) | |
| Isolated DVT of the lower extremity | 27 (44.3) |
| Isolated PE | 25 (41.0) |
| Combined DVT of the lower extremity and PE | 2 (3.3) |
| Isolated DVT of the upper extremity | 1 (1.6) |
| Internal jugular vein thrombosis | 1 (1.6) |
| Portal vein thrombosis | 1 (1.6) |
| Sinus vein thrombosis | 1 (1.6) |
| Inferior caval vein thrombosis | 1 (1.6) |
| Combined DVT of the lower extremity and portal vein thrombosis | 1 (1.6) |
| Combined DVT of the upper extremity and PE | 1 (1.6) |
| Classification of tumor, n (%) | |
| Localized | 10 (16.4) |
| Distant metastasis | 24 (39.3) |
| Not classifiable (brain tumors and hematologic malignancies) | 27 (44.3) |
| Site of cancer, n (%) | |
| Breast | 2 (3.3) |
| Lung | 6 (9.8) |
| Stomach | 7 (11.5) |
| Colorectal | 9 (14.8) |
| Pancreas | 7 (11.5) |
| Kidney | 1 (1.6) |
| Prostate | 2 (3.3) |
| Brain (high-grade glioma) | 19 (31.2) |
| Lymphoma | 7 (11.5) |
| Multiple myeloma | 1 (1.6) |
| Median body mass index, kg/m2 (25th-75th percentile) | 25.1 (22.5-28.3) |
| Median baseline laboratory values (25th-75th percentile) | |
| Platelet count, ×109/L | 231 (185-309) |
| WBC count, ×109/L | 7.9 (6.3-11.1) |
| Hemoglobin, g/L | 12.6 (11.4-13.9) |
| Soluble P-selectin, ng/mL | 50.3 (36.9-65.5) |
| D-Dimer, μg/mL | 1.01 (0.57-2.66) |
| Clinical characteristic . | Value . |
|---|---|
| Median age at study entry, y (IQR) | 60 (50-66) |
| Sex, n (%) | |
| Female | 21 (34.4) |
| Male | 40 (65.6) |
| Site of thrombotic event, n (%) | |
| Isolated DVT of the lower extremity | 27 (44.3) |
| Isolated PE | 25 (41.0) |
| Combined DVT of the lower extremity and PE | 2 (3.3) |
| Isolated DVT of the upper extremity | 1 (1.6) |
| Internal jugular vein thrombosis | 1 (1.6) |
| Portal vein thrombosis | 1 (1.6) |
| Sinus vein thrombosis | 1 (1.6) |
| Inferior caval vein thrombosis | 1 (1.6) |
| Combined DVT of the lower extremity and portal vein thrombosis | 1 (1.6) |
| Combined DVT of the upper extremity and PE | 1 (1.6) |
| Classification of tumor, n (%) | |
| Localized | 10 (16.4) |
| Distant metastasis | 24 (39.3) |
| Not classifiable (brain tumors and hematologic malignancies) | 27 (44.3) |
| Site of cancer, n (%) | |
| Breast | 2 (3.3) |
| Lung | 6 (9.8) |
| Stomach | 7 (11.5) |
| Colorectal | 9 (14.8) |
| Pancreas | 7 (11.5) |
| Kidney | 1 (1.6) |
| Prostate | 2 (3.3) |
| Brain (high-grade glioma) | 19 (31.2) |
| Lymphoma | 7 (11.5) |
| Multiple myeloma | 1 (1.6) |
| Median body mass index, kg/m2 (25th-75th percentile) | 25.1 (22.5-28.3) |
| Median baseline laboratory values (25th-75th percentile) | |
| Platelet count, ×109/L | 231 (185-309) |
| WBC count, ×109/L | 7.9 (6.3-11.1) |
| Hemoglobin, g/L | 12.6 (11.4-13.9) |
| Soluble P-selectin, ng/mL | 50.3 (36.9-65.5) |
| D-Dimer, μg/mL | 1.01 (0.57-2.66) |
Information on the site of VTE and the site of cancer and distribution of laboratory parameters included in the risk scoring models.
DVT indicates deep venous thrombosis; and PE, pulmonary embolism.